The STEP Young phase 3 trial met its primary endpoint, demonstrating greater body mass index (BMI) reduction in children aged 6 to under 12 treated with once-weekly subcutaneous semaglutide compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results